Concise review ‐ Treatment of multiple myeloma in the very elderly: How do novel agents fit in?

This review gives an overview of the benefits and toxicities of the currently available treatments in very elderly MM patients with a focus on first-line treatment. In addition we discuss the role of geriatric assessment to optimize treatment efficacy in the more vulnerable cohort.